Telix Pharmaceuticals (NasdaqGS:TLX) FY Conference January 12, 2026 12:00 PM ET Company ParticipantsChristian Behrenbruch - CEOConference Call ParticipantsChris Cooper - AnalystNone - AnalystChris CooperWe'll have some important FDA meetings.Christian BehrenbruchOkay.Chris CooperOkay, good morning. Thanks for joining us here at the J.P. Morgan Healthcare Conference. My name is Chris Cooper. I cover Australian healthcare here at J.P. Morgan. For this session, we're very fortunate to be joined by Christian Be ...

Lumexa Imaging FY Conference Summary Company Overview - **Company Name**: Lumexa Imaging (NasdaqGS:LMRI) - **Industry**: Diagnostic Imaging - **Market Size**: $140 billion Total Addressable Market (TAM) growing at a 4% CAGR; Outpatient sector at $33 billion TAM growing at a 7% CAGR [7][22] Key Points Industry Dynamics - Diagnostic imaging is a dynamic industry driven by an aging population and advancements in treatment paradigms requiring advanced imaging technologies such as MRI, CT, and PET scans [7][22] - The outpatient imaging sector is experiencing significant growth, with a shift towards lower-cost service centers [22][18] Company Positioning - Lumexa Imaging is the second largest platform in the outpatient imaging space with 188 sites across 13 states, focusing on high-growth markets [7][8] - The company operates a scalable model with a strong joint venture partnership strategy, having completed 44 de novos since inception, including a record nine in the past year [9][12] Financial Metrics - Advanced imaging accounts for 63% of revenue and 36% of volume, indicating a premium revenue model [13][27] - The company has a 97% patient satisfaction rate and an NPS of 91, significantly higher than industry benchmarks [12][15] - Revenue from outpatient imaging centers constitutes over 80% of total revenue and EBITDA [10][12] Growth Strategy - Lumexa aims to continue expanding through de novos and acquisitions, targeting 8-10 new centers annually [9][50] - The company emphasizes same-store growth by maximizing schedules and building referral relationships [48][49] - There is a focus on leveraging advanced technology, including AI, to enhance operational efficiency and patient care [10][33] Joint Venture Model - The joint venture model with health systems allows for shared capital expenditures and operational efficiencies, differentiating Lumexa from competitors [51][52] - The company has identified over 100 potential health system partners across top markets, many of whom currently lack imaging partnerships [43] Labor Market and Staffing - Lumexa benefits from a favorable labor market for radiologists and technologists, with better retention rates than industry averages [53] - The company provides flexibility and job satisfaction for staff, contributing to lower turnover [53] Future Outlook - The company is focused on maintaining a strong balance sheet while pursuing growth opportunities, with a commitment to transparency and communication with stakeholders [49][56] - Investors are expected to appreciate the consistency and quality of Lumexa's growth as it continues to establish itself as a leading outpatient imaging provider [55] Additional Insights - The outpatient imaging industry remains highly fragmented, with Lumexa and its largest competitor, RadNet, accounting for less than 10% of the market [25] - The company’s operational model allows for quick scalability and adaptability in response to market demands [30][41] - Lumexa's strategic partnerships and technology investments are designed to enhance patient experience and operational efficiency, positioning the company for sustained growth [34][36]

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and regulatory compliance, which resulted in significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, leading to a 21% decline in stock price [2][6]. - The SEC is questioning the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) at third-party manufacturers [3][6]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives overstated the developmental progress of therapeutic candidates and misrepresented the reliability of their supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, contradicting claims of "great progress" and "global manufacturing capability" [3][4]. Investor Impact - Investors who purchased Telix ADSs during the Class Period (February 21, 2025 – August 28, 2025) reportedly suffered substantial losses due to undisclosed flaws in supply chain and therapeutic progress [5][6]. - The cumulative effect of the regulatory disclosures led to a sharp decline in Telix ADSs, with a notable 21% drop following the final regulatory news [6]. Next Steps for Investors - Hagens Berman encourages affected Telix investors to contact the firm to discuss their rights and potential recovery options [4][5].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock [2][8]. - The SEC is investigating Telix's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [8]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives overstated the developmental progress of its therapeutic candidates and misrepresented the reliability of its third-party supply chain and manufacturing partners [2][3]. - Specific failures cited include deficiencies in Chemistry, Manufacturing, and Controls (CMC) and Form 483 notices issued to third-party manufacturers, which were allegedly concealed from investors [3][8]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [8]. - The firm representing the investors, Hagens Berman, is actively advising those who suffered losses due to undisclosed flaws in the supply chain and therapeutic progress [5][4].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, which resulted in significant investor losses [1][2][3]. Regulatory Setbacks - Telix Pharmaceuticals faced regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, leading to a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, TLX591 and TLX592, suggesting misleading statements about their advancement [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures allegedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is encouraging affected investors to contact them to discuss their rights and potential recovery options [4][5].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][7]. - The SEC is investigating Telix for potentially misleading disclosures about the development of its prostate cancer therapeutic candidates [7]. Allegations of Misrepresentation - The complaint claims that Telix and its executives overstated the progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - It alleges a dual regulatory failure, with the SEC questioning development disclosures and the FDA rejecting a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures led to substantial losses for investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is urging affected investors to contact them to discuss their rights and potential recovery [4][5].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to alleged misstatements regarding the progress of its prostate cancer drug TLX591 and deficiencies in its third-party manufacturing processes, leading to significant investor losses [2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value [2][7]. - The SEC is investigating the company's disclosures related to the development of its therapeutic candidates, suggesting misleading statements about their advancement [7]. - The FDA rejected the Zircaix application, citing severe deficiencies in Chemistry, Manufacturing, and Controls (CMC), and issued Form 483 notices to two third-party supply chain partners, revealing foundational weaknesses that were allegedly concealed [7]. Allegations of Misstatements - The complaint alleges that Telix and its executives materially overstated the developmental progress of its therapeutic candidates and misrepresented the reliability and regulatory compliance of its third-party supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, making the company's claims of "great progress" and "truly global manufacturing capability" materially false [3]. Investor Impact - The cumulative effect of the regulatory disclosures led to a sharp decline in Telix ADSs, with a notable 21% drop following the final regulatory news, resulting in significant damages for investors who purchased TLX ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][7]. - The SEC is investigating Telix's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [7]. - The FDA rejected Telix's Zircaix application, citing severe deficiencies in Chemistry, Manufacturing, and Controls (CMC), and issued Form 483 notices to two third-party supply chain partners, revealing foundational weaknesses that were allegedly concealed [7]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives materially overstated the developmental progress of its therapeutic candidates and misrepresented the reliability and regulatory compliance of its third-party supply chain and manufacturing partners [2][3]. - The complaint claims that these documented failures were material and concealed, making the company's claims of "great progress" and "truly global manufacturing capability" materially false [3]. Investor Impact - The cumulative effect of the regulatory disclosures allegedly caused Telix ADSs to fall sharply, leading to damages for investors who purchased TLX ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is urging Telix investors who suffered substantial losses to contact them to discuss their rights [4][5].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Setbacks - Telix faced multiple regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of its therapeutic candidates and misrepresented the reliability of its third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is actively advising investors who suffered substantial losses due to undisclosed flaws in the supply chain and therapeutic progress [5][6].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Setbacks - Telix Pharmaceuticals faced multiple regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting potential misleading statements [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is actively advising affected investors to discuss their rights and potential recovery options [4][5].